Patrys Limited (ASX:PAB)

Australia · Delayed Price · Currency is AUD

0.0300

-0.0020 (-6.25%)

Oct 9, 2026, 2:43 PM AEST

Market Cap	17.47M +90.5%
Revenue (ttm)	8.99K -98.9%
Net Income	-3.42M
EPS	-0.01
Shares Out	582.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	990,343
Open	0.0310
Previous Close	0.0320
Day's Range	0.0300 - 0.0310
52-Week Range	0.0150 - 0.0520
Beta	1.27
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About Patrys

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases. The Company’s portfolio includes an injectable quetiapine program for the treatment of delirium and its versatile deoxymab antibody platform, including PAT-DX1 and PAT-DX3, which is being developed for applications in inflammatory and autoimmune diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2006

Employees 10

Stock Exchange Australian Securities Exchange

Ticker Symbol PAB

Full Company Profile

Financial Performance

In fiscal year 2026, Patrys's revenue was 8,985, a decrease of -98.92% compared to the previous year's 828,540. Losses were -3.42 million, 13.3% more than in 2025.

Financial Statements